logo

Centre of Evidence of Dermatology Best practice guidelines

Guidelines hidradenitis suppurativa Updated on august 2019

Responsibility


The information provided by this website comes from sources deemed reliable. However, the French Dermatology Society recommends that the user ensure the validity of this information. Some may prove to be erroneous or be subject to typos or display errors.

The use of this data is under the sole responsibility of the user. The French Dermatology Society cannot be blamed for a misinterpretation of the data provided by the site, or in the event of erroneous information. This decision tree and all the contents of this site have been developed in the context of updated data from science according to the HAS methodology, expert opinions and reviewers of the various documents and in the context of the French healthcare system.


Associated measures

Back to decision-making tree Print last updated on 30/03/2020

Psychological support

The psychological impact of HS must be evaluated by physicians. If necessary, a psychologist or psychiatrist may be called upon for a specialist opinion.

Pain management

The level of proof in studies regarding pain management is currently insufficient to make recommendations on specific pain-management strategies in HS.

The work group recommends following the WHO guidelines according to whether pain is nociceptive (score of 1 to 3) and/or neuropathic. Considering the risk of infectious complications, the work group cannot recommend the use of anti-inflammatory drugs (NSAIDs, corticosteroids) for pain management.

Scale for pain assessment and treatment

PAIN TREATMENT
The World Health Organization scale for pain assessment and treatment (VAS)
Mild Pain (VAS 1-3) Paracetamol: (Dafalgan®, Doliprane®, Efferalgan®)
Moderate Pain (VAS 4-6) Paracetamol + Codeine Phosphate: (Dafalgan codeine®, Codoliprane®, Efferalgan codeine®), Tramadol Hydrochlorhyde (Topalgic®, Contramal®), Paracetamol + Tramadol Hydrochlorhyde: (Ixprim®)
Severe Pain (VAS 7-10) Actiskenan®, Skenan® LP, Oxynorm®, Oxycontin® LP, Moscontin®, Kapanol® LP, Durogesic®
  • Was this article helpful to you?
  • Your opinion counts!

    This notice will not be published on this site, but only sent to the publication management. Your email will only be used to reply to you if we deem it necessary. No response will be sent to any request for medical advice via this form.


read contraception

Centre of Evidence of Dermatology Centre of Evidence of Dermatology logo
Work
10 cité Malesherbes
75009Paris
Île-de-France
FRANCE
Work +33.1 43 27 01 56
Fax +33.1 43 27 01 86
centredepreuvesdermato@sfdermato.org